Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023 Addition of GPR40 agonist discovery...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,Quebec ,Pointe Claire ,Canadian ,Kaitlin Gallagher ,Bruce Pritchard ,Nicole Rusaw ,Shrinal Inamdar ,Exchange Commission ,Prnewswire Liminal Biosciences Inc ,Antagonist Development Plan ,Securities Exchange ,Agonist Development Plan ,Liminal Biosciences Inc ,Nasdaq ,Nasdaq Capital ,Chief Financial Officer ,Gary Bridger ,Interim Chief Scientific Officer ,Chief Executive Officer ,Strategic Advisor ,Interim Chief Scientific ,Nasdaq Capital Market ,Nasdaq Listing Rule ,Year Ended December ,Securities Act ,Securities Exchange Act ,Liminal Bioscience ,Canadian Securities Administrators ,Annual Report ,Associate Director ,Investor Relations ,Media Contact ,